Skip to main content

Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

By: Newsfile

Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints.

In July 2022, the Company announced that it had completed processing of the patient samples related to the SMM study and submitted the laboratory results to the Mayo Clinic for review and analysis. TELO intends to submit the final findings of the study for presentation at the American Society of Hematology (ASH) annual meeting scheduled for December 2022.

The Company's TeloView®-based test for SMM has the potential to identify high-risk SMM patients who will benefit from earlier treatment intervention; significantly, the test also has the potential to predict the larger subset of low-risk patients who have a more stable form of the disease and do not require treatment. Low-risk SMM patients may be tested up to every three months on an ongoing basis to monitor their status without the need for treatment intervention. TELO, in consultation with industry leaders, estimates that there are over 200,000 patients in the USA that may benefit from its TeloView® test for SMM, with a potential total addressable market of over 500,000 tests per year.

Based on the Company's interim results and as part of its commercialization plan to introduce TeloView® as a prognostic test across the spectrum of multiple myeloma ("MM") disease; TELO is also pleased to announce that it will be forming a MM clinical advisory board. The board will be made up of leading clinicians in the field with the purpose of guiding the Company's product launch and clinical adoption efforts for the TeloView® test for MM and its precursors.

"We are very happy to achieve these interim results," said Sherif Louis, PhD, and TELO's CEO. "Utilizing the TeloView® test with our new automation technology on independent SMM samples that are difficult to diagnose, is an important step towards proving our technology can work in the clinic and in a commercial setting. We are also looking forward to establishing a multiple myeloma advisory board of distinguished clinicians to help us introduce the TeloView® test commercially in the management of multiple myeloma, particularly the management of high-risk SMM patients."

About Smoldering Multiple Myeloma

SMM is a biologic precursor to MM, a deadly cancer that forms in plasma cells, a type of white blood cell. Typically, SMM is asymptomatic, but approximately 15% of SMM patients transition to active MM every year, which involves marked pain, the risk of bone fractures, and other debilitating symptoms. MM has an average five-year survival rate of approximately 55%. Identifying high-risk SMM patients who will transition to active MM is a critical unmet need in the management of MM and precursor its precursors.

About ASH Annual General Meeting

The American Society of Hematology represents healthcare professionals involved in the management of blood disorders including cancer. The ASH annual meeting is one of the top clinical international meetings focused on blood cancers. ASH attracts more than 30,000 attendees, predominantly clinicians.

About TELO

Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, TELO is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information please visit

For further information, please contact:

Hugh Rogers

MaRS Centre, South Tower,
101 College Street, Suite 200,
Toronto, ON, M5G 1L7

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView® platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.